Pradelli, L. (2014) “Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients”, Farmeconomia. Health economics and therapeutic pathways, 15(4), pp. 101–112. doi: 10.7175/fe.v15i4.971.